Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
Plain-language summary
This Phase 2 trial is evaluating tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, and other medications as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone (DRUG): tislelizumab: 200mg on d1 every 3 weeks; chidamide: 20mg twice a week at least 3 days apart; cyclophosphamide: 750mg/m2 on Day 1 of each cycle, every 4 weeks; mitoxantrone liposomes: 20mg/m2 on Day 1, every 4 weeks; prednisone: 100mg/day on Day 1 to Day 5 of each course, every 4 weeks.
- Drugs / treatments
- tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details